Recent commentary on Surgery Partners (SGRY) from Cantor Fitzgerald, highlighting expectations for profitability and net income growth this year despite softer second quarter operating trends, pushed the stock up 2.7% in the latest session.

That move sits on top of a 41.5% 90 day share price return and 25.1% 30 day share price return. However, Surgery Partners still has a 1 year total shareholder return that declined 22.2%, pointing to improving but still rebuilding momentum.

If you are looking beyond Surgery Partners for other healthcare related ideas, now could be a good time to scan for companies using our healthcare focused AI stocks screener, 40 healthcare AI stocks

With Surgery Partners now trading close to analyst price targets and recent gains lifting the stock off its lows, the key question is whether current levels still leave room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 4% Undervalued

The most followed narrative currently pegs Surgery Partners' fair value at about $17.95, very close to the last close of $17.23. This keeps the focus firmly on how its future earnings story could justify that gap.

The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution.

Want to see what is underpinning that fair value reset? The narrative leans on steady revenue expansion, margin repair and a future earnings multiple that assumes material profitability progress. Curious which specific growth and margin paths need to line up for Surgery Partners to meet that outlook?

Result: Fair Value of $17.95 (UNDERVALUED)

However, Surgery Partners still faces pressure from rising interest expenses and slower than planned acquisitions, either of which could undermine the margin repair narrative that investors are watching.

Next Steps

If the mixed sentiment around Surgery Partners has you curious, take a moment to review the underlying data yourself. Move quickly to shape your own view by looking over the 3 key rewards

Looking for more investment ideas beyond Surgery Partners?

If you like what you see with Surgery Partners but do not want to stop there, use Simply Wall Street's screeners to quickly surface more focused opportunities.

• Pinpoint potential turnaround plays by scanning for underpriced companies with resilient fundamentals using the 43 high quality undervalued stocks.
• Prioritise capital preservation by zeroing in on companies that pass strict balance sheet checks through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by hunting for under-followed quality stocks via the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.